Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal | Stock Market News
Nuvalent's shares surged 39% to $123 after GlaxoSmithKline agreed to acquire the cancer drug developer for $10.6 billion, enhancing its oncology portfolio.